ÓÄÊ 616.24-088.444:616.61:612.46 Îñíîâíûå ïàòîôèçèîëîãè ... ·...
TRANSCRIPT
ÓÄÊ 616.24-088.444:616.61:612.46
Îñíîâíûå ïàòîôèçèîëîãè÷åñêèå ìåõàíèçìû ïî÷å÷íûõ ïîðàæåíèé, îáóñëîâëåííûõ
ñèíäðîìîì îáñòðóêòèâíîãî àïíîý-ãèïîïíîý ñíà: Абстракт
Ë.Ã. Äãåðÿí, Ã.À. Ïîäîñÿí, Ã.Ë. Õàíäàíÿí, À.Ê. Øóêóðÿí,
Ï.À. Çåëâåÿí
Ðàññìàòðèâàþòñÿ îñíîâíûå ïðè÷èíû ðàçâèòèÿ ïîðà-æåíèé ïî÷åê ó áîëüíûõ ñ ñèíäðîìîì
îáñòðóêòèâíîãî àïíîý-ãèïîïíîý ñíà.
Ìåäèöèíñêèé Âåñòíèê Ýðåáóíè, 2012, 2(50), 19-29
1. Gulleminault C., Dement W. eds. Sleep apnea syndromes. New York, Alan R. Liss Inc. 1978,pp.1-365.
2. Stradling J. Obstructive sleep apnoea: defini-tions, epidemiology, and natural history. Thorax
1995,50:683-9.
3. Shahar E., Whitney C., Redline S., et al. Sleep-disordered breathing and cardiovascular disease: cross
sectional results of the Sleep Heart Health Study. Am. J. Respir. Crit. Care Med.,
2001;163:19-25.
4. Stigter H., Lammers G., Rooyackers J., et al. Sleep disorders and the ability to drive, revision oflegislation. Ned Tijdschr Geneeskd 2009;153:A690.
5. McNicholas W., Bonsigore M. Management Committee of EU COST ACTION B26. Sleep apnoeaas an independent risk factor for cardiovascular disease: current evidence, basic mechanisms andresearch priorities. Eur. Respir. J., 2007;29:1:156-78.
6. Gami A., Howard D., Olson E., et al. Day-night pattern of sudden death in obstructive sleep apnea.N. Engl. J. Med., 2005;352:1206-14.
7. Pankow W., Lies A., Lohmann F., et al. Sleep-disordered breathing and hypertension. N. Engl.
J. Med., 2000;343:966-7.
8. Peppard P., Young T., Palta M., et al. Prospec-tive study of the association between sleep-
disordered breathing and hypertension. N. Engl.
J. Med., 2000;342:1378-84.
9. Robinson G., Stradling J., Davies R. Obstructive sleep apnoea/hypopnoea syndrome andhypertension. Thorax 2004;59:12:1089-94.
10. Зелвеян П.А., Ощепкова Е.В., Арабидзе Г.Г. Синдром апноэ во сне и артериальная гипертония. Тер.aрх. 1997;9:76-80.
11. Зелвеян П.А., Ощепкова Е.В., Буниатян М.С., и др. Особенности суточного профиля АД у больныхмягкой и умеренной формами артериальной гипертонией с синдромом апноэ/гипопноэ во сне. Тер.арх. 2001;9;8-13.
12. Van Houwelingen K., van Uffelen R., van Vliet
A. The sleep apnoea syndromes. Eur. Heart. J., 1999,20:12:858-66.
13. Williams A., Houston D., Finberg S., et al. Sleep apnea syndrome and essential hyperten-sion.Amer. J. Cardiol., 1985;55:1019-22.
Литература
14. Silverberg D., Oksenberg A., Radwan H., Iaina
A. Is obstructive sleep apnea a common cause ofessential hypertension? Israel. J. M. Sci.,
1995;31:527-35.
15. Silverberg D., Oksenberg A. Essential and
secondary hypertension and sleep-disorderedbreathing: a unifying hypothesis. J. Hum.
Hypertension, 1996;10:353-63.
16. Quan S., Gersh B. Cardiovascular consequences
of sleep-disordered breathing: Past, present and
future: Report of a workshop from the national
center on sleep disorders research. Circulation
2004;109:951-7.
17. Hla K., Skatrud J., Finn L., et al. The effect of
correction of sleep-disordered breathing onblood pressure in untreated hypertension. Chest.,
2002;122:4:1125-32.
18. Faulx M., Storfer-Isser A., Kirchner H., et al.
Obstructive sleep apnea is associated withincreased urinary albumin excretion. Sleep,
2007;30:923-9.
19. Fletcher E. Obstructive sleep apnea and the
kidney. J Am Soc Nephrol 1993;4:1111-21.
20. Sklar A., Chaudhary B. Reversible Proteinuriain Obstructive Sleep Apnea Syndrome. Arch.
Intern, Med., 1988;148:87-9.
21. Chaudhary B., Sklar A., Chaudhary T., et al.
Sleep apnea, proteinuria and nephrotic
syndrome. Sleep 1988;11:69-74.
22. Chaudhary B., Rehman O., Brown T.Proteinuria in patients with sleep apnea. J.
Family Practice, 1995;40:139-41.
23. Kimmel R., Miller G., Mendelson W. Sleepapnea syndrome in chronic renal disease. Am. J.
Med., 1989;86:308-14.
24. Mendelson W., Wadhwa N., Greenberg H. et al.
Effects of hemodialysis on sleep apnea
syndrome in end stage renal disease. Clinical
Nephrol., 1990;33:247-51.
25. Sklar A., Chaudhary B., Harp R. Nocturnal
urinary protein excretion rates in patients withsleep apnea. Nephron, 1989;51:35-8.
26. Praga M., Hernandez E., Andres A., et al.
Effects of body-weight loss and captopril
treatment on proteinuria associated with obesity.Nephron, 1995;70:35-41.
27. Bailey R., Lynn K., Burry A., et al. Proteinuria,
glomerulomegaly and focal glomerulosclerosis
in a grossly obese man with obstructive sleepapnea. Aust. NZ J. Med., 1989;19:473-4.
28. Fine L., Norman J. Chronic hypoxia as a
mechanism of progression of chronic kidney
diseases: from hypothesis to novel therapeutics.Kidney Int., 2008;4:867-72.
29. Mello P., Franger M., Boujaoude Z., et al. Night
and day proteinuria in patients with sleep apnea.Am. J. Kidney Dis., 2004;44:636-41.
30. Nangaku M. Chronic hypoxia and tubulointersti-
tial injury: a final common pathway to end-stagerenal failure. J. Am. Soc. Nephrol., 2006;17:17-
25.
31. Bratel T., Ljungman S., Runold M., Stenvinkel
P. Renal function in hypoxaemic chronic
obstructive pulmonary disease: effects of long-term oxygen treatment. Respir. Med., 2003;
97:308-16.
32. Kinebuchi S., Kazama J., Satoh M., et al.
Shortterm use of continuous positive airway
pressure ameliorates glomerular hyperfiltration
in patients with obstructive sleep apnoea
syndrome. Clin. Sci (Lond) 2004;107:317-22.
33. Schmidt M., Ledderhos C., Honig A. Kidney
function during arterial chemoreceptor stimula-
tion. I. Influence of unilateral renal nerve
section, bilateral cervical vagotomy, constant
artificial ventilation and carotid body che-
moreceptor inactivation. Biomed Biochim Acta
1985;44:695-709.
34. Krieger J., Imbs J., Schmidt M., et al. Renal
function in patients with obstructive sleep
apnea. Arch. Intern. Med., 1988;148:1337-40.
35. Warley A., Stradling J. Abnormal diurnal
variation in salt and water excretion in patients
with obstructive sleep apnea. Clin. Sci.,
1988;74:183-5.
36. Crabtree D., Morgan B., Skatrud J. Chemoreflex
sensitization augments sympathetic vasomotor
outflow in awake humans. Am. Rev. Respir.
Dis., 1993;147:A1015.
37. Fletcher E., Miller J., Schaaf J., et al. Urinary
cathecolamines before and after tracheostomy in
patients with obstructive sleep apnea and
hypertension. Sleep., 1987;10:35-44.
38. Xie A., Skatrud J., Puleo D., et al. Exposure to
hypoxia produces long-lasting sympatheticactivation in humans. J. Appl. Physiol, 2001;
91:1555-62.
39. Greenberg H., Sica A., Batson D., et al. Chronic
intermittent hypoxia increases sympathetic
Ë.Ã. Äãåðÿí, Ã.À. Ïîäîñÿí, Ã.Ë. Õàíäàíÿí, À.Ê. Øóêóðÿí, Ï.À. Çåëâåÿí
responsiveness to hypoxia and hypercapnia. J.
Appl. Physiol., 1999;86:298-305.
40. Cutler M., Swift N., Keller D., et al. Hypoxia-
mediated prolonged elevation of sympathetic
nerve activity after periods of intermittenthypoxic apnea. J. Appl. Physiol, 2004;96:754-
61.
41. Vgontzas A., Papanicolaou D., Bixler E., et al.
Sleep apnea and daytime sleepiness and fatigue:
Relation to visceral obesity, insulin resistance,
and hypercytokinemia. J Clin Endocrinol Metab
2000;85:1151-8.
42. Strhol K., Novak R., Singer W., et al. Insulin
levels, blood pressure and sleep apnea. Sleep
1994;17:614-8.
43. Fletcher E., Orolinova N., Bader M. Blood
pressure response to chronic episodic hypoxia:
the renin-angiotensin system. J Appl Physiol
2002;92:627-33.
44. Cortelli P., Parchi P., Sforza E., et al. Cardio-
vascular autonomic dysfunction in normotensive
awake subjects with obstructive sleep apnoea
syndrome. Clin Auton Res 1994;4:57-62.
45. Lai C., Yang C., Hsu Y., et al. Enhanced
sympathetic outflow and decreased baroreflex
sensitivity are associated with intermittent
hypoxia-induced systemic hypertension in
conscious rats. J. Appl. Physiol., 2006; 100:
1974-82.
46. Phillips B., Narkiewicz K., Pesek C., et al.
Effects of obstructive sleep apnea on endothelin-
1 and blood pressure. J Hypertens 1999;17:61-6.
47. Narkiewicz K., van de Borne P., Montano N., et
al. Contribution of tonic chemoreflex activation
to sympathetic activity and blood pressure in
patients with obstructive sleep apnea.
Circulation 1998;97:943-5.
48. Mills P., Kennedy B., Loredo J., et al. Effects of
nasal continuous positive airway pressure and
oxygen supplementation on norepinephrine
kinetics and cardiovascular responses inobstructive sleep apnea. J. Appl. Physiol.,
2006;100:343-8.49. Grote L., Kraiczi H., Hedner J. Reduced α- and
β2-adrenergic vascular response in patients with
obstructive sleep apnea. Am. J. Respir. Crit Care
Med., 2000;162:1480-7.
50. Greenberg D., Chan J., Sampson H. Endothelins
and the nervous system. Neurology 1992;42:25-
31.
51. Marasciulo F., Montagnani M., Potenza M.
Endothelin-1: the yin and yang on vascular
function. Curr Med Chem 2006;13:1655-65.
52. Haight J., Djupesland P. Nitric oxide and
obstructive sleep apnea. Sleep Breath 2003;
7:53-62.
53. Ip M., Lam B., Chan L., et al. Circulating nitric
oxide is suppressed in obstructive sleep apnea
and is reversed by nasal continuous positive
airway pressure. Am J Respir Crit Care Med
2000;162:2166-71.
54. Zhao H., Chen B., Cao J., et al. Effects of
obstructive sleep apnea style intermittent
hypoxia on endothelin-1, nitric oxide, and nitric
oxide synthase in endothelium: experiment with
human umbilical vein endothelial cells.
Zhonghua Yi Xue Za Zhi 2007 21;87:31:2189-
92.
55. Grimpen F., Kanne P., Schulz E., et al.
Endothelin-1 plasma levels are not elevated in
patients with obstructive sleep apnoea. Eur
Respir J 2000;15:320-5.
56. Jordan W., Reinbacher A., Cohrs S. et al.
Obstructive sleep apnea: plasma endothelin-1
precursor but not endothelin-1 levels are
elevated and decline with nasal continuous
positive airway pressure. Peptides 2005;
26:1654-60.
57. Jordan W., Cohrs S., Degner D. et al. Evaluation
of oxidative stress measurements in obstructive
sleep apnea syndrome. J. Neural. Transm.,
2006;113:239-54.
58. Lavie L. Obstructive sleep apnoea syndrome –an oxidative stress disorder. Sleep Med. Rev.
2003;7:35-51.
59. Cohen R. The role of nitric oxide and other
endothelium-derived vasoactive substances in
vascular disease. Prog Cardiovasc Dis 1995;
38:105-28.
60. Carlson J., Rangemark C., Hedner J. Attenuated
endothelium-dependent vascular relaxation in
patients with sleep apnoea. J Hypertens
1996;14:577-84.
61. Kato M., Roberts-Thomson P., Phillips B., et al.
Impairment of endothelium-dependent vasodila-
tion of resistance vessels in patients with
obstructive sleep apnea. Circulation 2000; 102:
2607-10.
62. Schulz R., Schmidt D., Blum A., et al. Decrea-
sed plasma levels of nitric oxide derivatives in
Îñíîâíûå ïàòîôèçèîëîãè÷åñêèå ìåõàíèçìû ïî÷å÷íûõ ïîðàæåíèé, îáóñëîâëåííûõ ñèíäðîìîì îáñòðóêòèâíîãî àïíîý-ãèïîïíîý ñíà
obstructive sleep apnoea: response to CPAP
therapy. Thorax 2000;55:1046-51.
63. Fletcher E., Bao G., Li R. Renin activity and
blood pressure in response to chronic episodic
hypoxia. Hypertension 1999;34:309-14.
64. Bostrom K., Hedner J., Melander O., et al.
Interaction between the angiotensin-converting
enzyme gene insertion/deletion polymorphism
and obstructive sleep apnoea as a mechanism for
hypertension. J Hypertens 2007;25:779-83.
65. Millman R., Redline S., Carlisle C., et al.
Daytime hypertension in obstructive sleep
apnea. Prevalence and contributing risk factors.
Chest 1991;99:861-6.
66. Kraiczi H., Hedner J., Peker Y., et al. Increased
vasoconstrictor sensitivity in obstructive sleep
apnea. J Appl Physiol 2000;89:493-8.
67. Moller D., Lind P., Strunge B., et al. Abnormal
vasoactive hormones and 24-hour blood
pressure in obstructive sleep apnea. Am J
Hypertens 2003;16:274-80.
68. Lavie L. Sleep-disordered breathing and cere-
brovascular disease: a mechanistic approach.
Neurol Clin 2005;23:1059-75.
69. Foster G., Poulin M., Hanly P. Intermittent
hypoxia and vascular function: implications for
obstructive sleep apnoea. Exp Physiol
2007;92:51-65.
70. Clausen P., Jensen J., Jensen G., et al. Elevated
urinary albumin excretion is associated with im-
paired arterial dilatory capacity in clinically
healthy subjects. Circulation 2001;103:14:1869-
74.
71. Faulx M., Larkin E., Hoit B., et al. Sex
Influences Endothelial Function in Sleep-
Disordered Breathing. Sleep 2004;27:6:1113-20.
72. Dyugovskaya L., Lavie P., Lavie L. Increased
adhesion molecules expression and production
of reactive oxygen species in leukocytes of sleepapnea patients. Am. J. Respir. Crit. Care Med.,
2002;165:934-9.
73. Dyugovskaya L., Lavie P., Lavie L. Lym-
phocyte activation as a possible measure of
atherosclerotic risk in patients with sleep apnea.Ann. N. Y. Acad. Sci., 2005;1051:340-50.
74. Altin R., Ozdemir H., Mahmutyazicioglu K., et
al. Evaluation of carotid artery wall thickness
with high-resolution sonography in obstructivesleep apnea syndrome. J. Clin. Ultrasound,
2005;33:80-6.
75. Drager L., Bortolotto L., Lorenzi M., et al. Early
signs of atherosclerosis in obstructive sleep
apnea. Am. J. Respir. Crit. Care Med., 2005;
172:613-8.
76. Saletu M., Nosiska D., Kapfhammer G., et al.
Structural and serum surrogate markers of
cerebrovascular disease in obstructive sleep
apnea (OSA): association of mild OSA with
early atherosclerosis. J Neurol., 2006;253:746-
52.
77. Schulz R., Hummel C., Heinemann S., et al.
Serum levels of vascular endothelial growth
factor are elevated in patients with obstructive
sleep apnea and severe nighttime hypoxia. Am.
J. Respir. Crit. Care. Med., 2002;165:67-70.
78. Lavie L., Kraiczi H., Hefetz A., et al. Plasma
vascular endothelial growth factor in sleep
apnea syndrome: effects of nasal continuous
positive air pressure treatment. Am. J. Respir.
Crit Care Med., 2002;165:1624-8.
79. Wessendorf T., Thilmann A., Wang Y., et al.
Fibrinogen levels and obstructive sleep apnea in
ischemic stroke. Am. J. Respir. Crit Care Med.,
2000;162:2039-42.
80. Minoguchi K., Yokoe T., Tazaki T., et al.
Increased carotid intima-media thickness and
serum inflammatory markers in obstructive
sleep apnea. Am. J. Respir. Crit. Care. Med.,
2005;172:625-30.
81. Reuben D., Wachtel T., Brown P., et al.
Transient proteinuria in emergency medical
admissions. N. Engl. J. Med., 1982;306:1031-3.
82. Faustinella F., Uzoh C., Sheikh-Hamad D., et al.
Glomerulomegaly and proteinuria in a patient
with idiopathic pulmonary hypertension. J. Am.
Soc. Nephrol., 1997;8:1966-70.
83. Krieger J., Schmidt M., Sforza E. et al. Urinary
excretion of guanosine 3:5-cyclic mono-
phosphate during sleep in obstructive sleep ap-
noea patients with and without nasal continuous
positive airway pressure treatment. Clin. Sci.,
1989;76:31-7.
84. Krieger J., Laks L., Wilcox I. et al. Atrial
natriuretic peptide release during sleep in
patients with obstructive sleep apnoea before
and during treatment with nasal continuous
positive airway pressure treatment. Clin. Sci.,
1989;77:407-11.
85. Ichioka M., Hirata Y., Inase N. et al. Changes of
circulating atrial natriuretic peptide and
Ë.Ã. Äãåðÿí, Ã.À. Ïîäîñÿí, Ã.Ë. Õàíäàíÿí, À.Ê. Øóêóðÿí, Ï.À. Çåëâåÿí
antidiuretic hormone in obstructive sleep apnea
syndrome. Respiration 1992;59:164-8.
86. Krieger J., Follenius M., Sforza E., et al. Effects
of treatment nasal continous positive airway
pressure on atrial natriuretic peptide and argi-
nine vasopressin release during sleep in patients
with obstructive sleep apnoea. Clin. Sci., 1991;
80:443-9.
87. Loute G., Pieters D., Jadot J. et al. Effect of the
variation of hematocrit on the proteinuria of a
patient with polycythemia and congenital heart
disease. Nephron 1987;46:109-11.
88. Metcalf P., Baker J., Scott A. et al. Albuminuria
in people at least 40 years old: effect of obesity,
hypertension, and hyperlipidemia. Clin Chem
1992;38:1802-8.
89. Jerums G., MacIsaac R. Treatment of mic-
roalbuminuria in patients with type 2 diabetes
mellitus. Treat Endocrinol 2002; 1:3:163-73.
90. Stokholm K., Brochner-Mortensen J., Hoilund-
Carlsen P. Increased glomerular filtration rate
and adrenocortical function in obese women. Int
J Obes 1980;4:57-63.
91. Kasiske B., Crosson J. Renal disease in patients
with massive obesity. Arch. Intern. Med., 1986;
146:1105-9.
92. Ellis P. Renal enlargement in chronic corpulmonale. J. Clin. Pathol., 1961;14:552-6.
Îñíîâíûå ïàòîôèçèîëîãè÷åñêèå ìåõàíèçìû ïî÷å÷íûõ ïîðàæåíèé, îáóñëîâëåííûõ ñèíäðîìîì îáñòðóêòèâíîãî àïíîý-ãèïîïíîý ñíà